

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

200.1133CON

APPLICATION NO

10/689,866

APPLICANT

Benjamin OSHLACK et al.

FILING DATE

October 23, 2003

GROUP

1615

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A01	Gorelick, David A, "The Rate Hypothesis and Agonist Substitution Approaches to Cocaine Abuse Treatment," <i>Advances in Pharmacology</i> , Vol 42., (1998).
A02	U.S. General Accounting Office "Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem <i>Report to Congressional Requesters</i> ", December 2003
A03	Becker, A.B. et al., Abstract: "Transdermal Buprenorphine: Abuse Potential Assessment in Non-Opioid-Dependent Volunteers," (2001).
A04	Farré, Magi et al., "Pharmacokinetic Considerations in Abuse Liability Evaluation," <i>British Journal of Addiction</i> (1991) 86, pp. 1601-1606
A05	Brookoff, Daniel, "Abuse Potential of Various Opioid Medications," <i>Journal of General Internal Medicine</i> , Vol. 8 (December), 1993, pp. 688-690
A06	Cami, Jordi et al., "Mechanisms of Disease: Drug Addiction," <i>New England Journal of Medicine</i> Vol. 349 No. 10 September 4, 2003, pp. 975-986
A07	Quinn, David I. et al., "Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users," <i>Clin. Pharmacokinet.</i> Vol. 33, No. 5 (1997), pp.344-400.
A08	Marsch, Lisa A. et al., "Effects of Infusion Rate of Intravenously Administered Morphine on Physiological, Psychomotor, and Self-Reported Measures in Humans," <i>The Journal of Pharmacology and Experimental Therapeutics</i> Vol. 299, No. 3, pp. 1056-1065, (2001).
A09	de Wit, Harriet et al., "Rate of Increase of Plasma Drug Level Influences Subjective Response in Humans," <i>Psychopharmacology</i> (1992) 107:352-358.
A10	de Wit, Harriet et al., "Subjective and Behavioral Effects of Diazepam Depend on its Rate of Onset," <i>Psychopharmacology</i> (1993) 112:324-330.
A11	Nelson, Richard A. et al., "Effect of Rate of Administration on Subjective and Physiological Effects of Intravenous Cocaine in Humans," <i>Drug and Alcohol Dependence</i> 82 (2006) pp. 19-24.
A12	Kollins, Scott H. et al., "Comparison of Acute Behavioral Effects of Sustained-Release and Immediate-Release Methylphenidate," <i>Experimental and Clinical Psychopharmacology</i> Vol. 6, No. 4 (1998) pp. 367-374.
A13	Roset, Pere N. et al., "Modulation of Rate of Onset and Intensity of Drug Effects Reduces Abuse Potential in Healthy Males," <i>Drug and Alcohol Dependence</i> 64 (2001) pp. 285-298.
A14	Parasrampur, Dolly A. et al., "Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans," <i>J. Clin. Pharmacol.</i> (2007) 47; pp. 1476-1488.
A15	Compton, Wilson M. et al., "Abuse of Prescription Drugs and the Risk of Addiction," <i>Drug and Alcohol Dependence</i> 83S (2006) S4-S7.
A16	Volkow, Nora D., "Stimulant Medications: How to Minimize Their Reinforcing Effects?," <i>Am J Psychiatry</i> 163:3, March 2006, pp. 359-361.
A17	Volkow, Nora D. et al., "Variables that Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD," <i>Am J Psychiatry</i> 160:11, November 2003, pp. 1909-1918
A18	Mathias, "Rate and Duration of Drug Activity Play Major Roles in Drug Abuse, Addiction, and Treatment," <i>NIDA Notes: NIDA-Supported Research</i> , Vol. 12, No. 2, March/April 1997
A19	Griffiths, Roland R. et al., Abstract: "Relative Abuse Liability of Diazepam and Oxazepam: Behavioral and Subjective Dose Effects," <i>Psychopharmacology (Berl)</i> 84 (1984)
A20	Mewaldt, S. P. et al., Abstract "The Behavioral Actions of Diazepam and Oxazepam are Similar," <i>Psychopharmacology</i> June 1986 Vol. 88, No. 2.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.